BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20210314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20211107T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20220313T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20221106T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20230312T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20231105T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Dublin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:IST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:IST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:IST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Asia/Singapore
BEGIN:STANDARD
TZOFFSETFROM:+0800
TZOFFSETTO:+0800
TZNAME:+08
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220615T083000
DTEND;TZID=America/New_York:20220615T170000
DTSTAMP:20220527T210409Z
CREATED:20220527T210409Z
LAST-MODIFIED:20220527T210409Z
UID:55115-1655281800-1655312400@globalbiodefense.com
SUMMARY:VRBPAC Meeting to Review Pediatric (Infant - 5 Years) mRNA Vaccines
DESCRIPTION:The VRBPAC will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age\, and also to discuss amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 4 years of age. \nFDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. The Docket Number is FDA-2022-N-0904.
URL:https://globalbiodefense.com/event/vrbpac-meeting-to-review-pediatric-infant-5-years-mrna-vaccines/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=Ixm4UmldTGQ
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220619
DTEND;VALUE=DATE:20220624
DTSTAMP:20210226T210720Z
CREATED:20210226T210720Z
LAST-MODIFIED:20210226T210720Z
UID:48681-1655596800-1656028799@globalbiodefense.com
SUMMARY:ISPPD-12 International Symposium on Pneumococci and Pneumococcal Diseases
DESCRIPTION:Discover the latest achievements in the fight against the pneumococcus at the ISPPD-12 International Symposium on Pneumococci and Pneumococcal Diseases 19-23 June 2022 in Toronto. \nThis meeting was originally scheduled for Oct 2020. Given on-going safety concerns for in-person meetings due to COVID-19 during 2020-2021\, the in-person event was ultimately pushed to June 2022. \nThe event brings together professionals in the field to raise global awareness and improve standards of diagnosis\, prevention and treatment. \nHighlighted topics include: \n\nEpidemics\, outbreaks\, and special settings\nPneumococcal epidemiology\nVaccine effect on disease in children\nTrends in non-vaccine serotypes\nMathematical modeling\nDiagnosis and diagnostic assays\nAntimicrobial resistance\nConventional and molecular microbiology\nTreatment of pneumonia and pneumococcal disease\nGenetic sequencing\nPneumococcal colonization\nAdult vaccination strategies\nIndirect effects of paediatric programmes on disease in adults\nPneumococcal disease in persons with high-risk conditions\nPneumococcal vaccines in development\nCOVID effects on pneumonia and pneumococcal disease burden\nEffects of COVID on pneumoccoccal vaccine programmes\nManagement of community acquired pneumonia in the time of COVID\nEmerging data on SARS-CoV2 and pneumococcus interaction\n\nPlease visit the ISPPD-12 website for more information on how to participate.
URL:https://globalbiodefense.com/event/isppd-12-international-symposium-on-pneumococci-and-pneumococcal-diseases/
LOCATION:Sheraton Centre Toronto Hotel\, 123 Queen St W\, Toronto\, Ontario\, M5H 2M9
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220628T083000
DTEND;TZID=America/New_York:20220628T170000
DTSTAMP:20220527T213139Z
CREATED:20220527T213139Z
LAST-MODIFIED:20220527T213139Z
UID:55118-1656405000-1656435600@globalbiodefense.com
SUMMARY:VRBPAC Meeting on COVID-19 Vaccine Strain Composition Decisions
DESCRIPTION:The VRBPAC will meet in open session on 28 June 2022 to discuss whether and how the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified. \nFDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. \nThe Docket Number is FDA-2022-N-0905
URL:https://globalbiodefense.com/event/vrbpac-meeting-on-covid-19-vaccine-strain-composition-decisions/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=BFdzNUus_CE
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220629T120000
DTEND;TZID=America/New_York:20220629T170000
DTSTAMP:20220622T153805Z
CREATED:20220622T153805Z
LAST-MODIFIED:20220622T153805Z
UID:55703-1656504000-1656522000@globalbiodefense.com
SUMMARY:USG Policies for the Oversight of Life Sciences Dual Use Research of Concern
DESCRIPTION:The purpose of this meeting is to gather feedback from stakeholders about their experiences implementing these policies\, the effect of these policies in terms of achieving their stated goals\, the overarching definition of DURC\, and possible alternative approaches for the oversight and responsible conduct of DURC. \nThis feedback will also be used to inform the discussions of the National Science Advisory Board for Biosecurity (NSABB) in fulfillment their current charge to evaluate and analyze the DURC policies. \nRegistration is not required to view the webcast. \nREAD MORE: Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
URL:https://globalbiodefense.com/event/usg-policies-for-the-oversight-of-life-sciences-dual-use-research-of-concern/
CATEGORIES:Conference,Government Hosted
LOCATION:https://osp.od.nih.gov/event/virtual-stakeholder-engagement-meeting-on-usg-policies/
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220727
DTEND;VALUE=DATE:20220731
DTSTAMP:20220601T174333Z
CREATED:20220601T174333Z
LAST-MODIFIED:20220601T174333Z
UID:55589-1658880000-1659225599@globalbiodefense.com
SUMMARY:Toxins 2022 International Conference
DESCRIPTION:TOXINS 2022 will be held July 27-30\, 2022\, at the New Orleans Marriott in New Orleans\, Louisiana.\nThis is the foremost gathering for the latest developments in the basic science and clinical applications of botulinum and other neurotoxins. \nThe scientific program—presented by the world’s experts in their respective fields—will be of interest to basic scientists and clinicians in the fields of neurology\, physical medicine and rehabilitation\, dermatology\, aesthetic medicine\, ophthalmology\, otolaryngology\, urology\, gastroenterology\, and pain management. \nThe TOXINS conference is hosted by the International Neurotoxins Association. Due to restrictions associated with the global COVID-19 pandemic\, TOXINS 2021: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins\, was held as a virtual event 16-17 January 2021. The conference was a tremendous success with 1101 clinicians and scientists representing 63 countries participating. The event was also made available on demand and was accessed by 328 participants. \nJoin researchers and stakeholders at the TOXINS 2022 event in New Orleans. \n 
URL:https://globalbiodefense.com/event/toxins-2022-international-conference/
LOCATION:New Orleans Marriott\, 555 Canal Street\, New Orleans\, LA\, 70130\, United States
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220830T083000
DTEND;TZID=America/New_York:20220830T170000
DTSTAMP:20240623T192753Z
CREATED:20220829T230154Z
LAST-MODIFIED:20240623T192753Z
UID:56260-1661848200-1661878800@globalbiodefense.com
SUMMARY:Drug Development Considerations for the Prevention of Healthcare Associated Infections
DESCRIPTION:The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are co-sponsoring this public virtual workshop on August 30\, 2022. All meeting materials—including agenda\, panelist affiliations/disclosures\, speaker slides\, workshop recording\, and transcript—will be posted here shortly before and/or after the completion of the workshop. \n\nThe current state of development of pathogen-directed products used to prevent healthcare-associated infections (HAIs).\nEvidence supporting decolonization and pathogen reduction (in colonized patients) as a strategy to prevent infection and transmission of antimicrobial-resistant healthcare-associated pathogens.\nAntimicrobial resistance threats as potential targets for decolonization and pathogen reduction.\nChallenges and potential approaches to drug development and registration of products for the prevention of healthcare-associated infections.\n\nThis meeting will be held in virtual format only. Registration is required for online attendance and will be available until 12 p.m. EDT on August 29\, 2022.
URL:https://globalbiodefense.com/event/drug-development-considerations-for-the-prevention-of-healthcare-associated-infections/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20220831T120000
DTEND;TZID=America/Chicago:20220831T130000
DTSTAMP:20220829T173614Z
CREATED:20220829T173614Z
LAST-MODIFIED:20220829T173614Z
UID:56247-1661947200-1661950800@globalbiodefense.com
SUMMARY:Monkeypox: Updates in Evaluation and Management
DESCRIPTION:Discuss the current landscape of Monkeypox in the U.S and infection prevention considerations for evaluation and management in healthcare settings. \nDescribe the clinical presentation in ambulatory and inpatient settings\, as well as the role of supportive and antiviral treatments. \nThis NETEC webinar series presentation will bring together health care practitioners from Massachusetts General Hospital\, Cedars-Sinai\, and NYC Health + Hospitals to share their first-hand experiences caring for patients with monkeypox. Panelists will discuss the current landscape of monkeypox\, infection prevention in health care settings\, and the role of supportive and antiviral treatments in patient care. Panelists will also answer audience questions submitted during webinar registration. \nPANELISTS \nJonathan Grein\, MD\nDirector of Hospital Epidemiology\,\nCedars-Sinai Medical Center\, Los Angeles \nErica S. Shenoy\, MD\nAssociate Chief\, Infection Control Unit\nMedical Director\, Regional Emerging Special Pathogens Treatment Center\nMassachusetts General Hospital \nKevin L. Ard\, MD\, MPH\nDirector\, Sexual Health Clinic\,\nMassachusetts General Hospital\nAssistant Professor\, Harvard Medical School \nPlease visit the NETC website to register for Monkeypox: Updates in Evaluation and Management.
URL:https://globalbiodefense.com/event/monkeypox-updates-in-evaluation-and-management/
CATEGORIES:Conference,Webinar-Webcast
LOCATION:https://unmc.zoom.us/webinar/register/WN_hETaz1ecTRuqvb_mKoemtg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220912
DTEND;VALUE=DATE:20220914
DTSTAMP:20220830T001753Z
CREATED:20220830T001521Z
LAST-MODIFIED:20220830T001753Z
UID:56267-1662940800-1663113599@globalbiodefense.com
SUMMARY:Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
DESCRIPTION:The 21st Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) public meeting is tentatively being planned as an in-person event on September 12 and September 13\, 2022. The meeting will focus on pandemic preparedness and AMR policy. \nHighlighted topics include: \n\nUnderstanding the Human Diagnostic Communication Network (Labs\, Public Health Departments\, and Providers)\nInfection Prevention and Control for Resistant Pathogens during a Medical Surge\nLeveraging the Existing Pipeline of Available Vaccines and Therapeutics while Developing New AMR MCMs (Human)\nDeveloping New Human Diagnostics in an Emergency Situation: What’s Expected\, Needed\, and How We Get What We Need\nA Pandemic Response from a Global Perspective\nThe Agricultural Workforce: Human Health Risk and the Role of Workers as Vectors of Transmission\nThe Role of Associations in Pandemic Response and Dissemination of Information\nImpact of a Public Health Emergency on Human Antibiotic Stewardship Practices\nDiagnosing Fungal Infections and Resistance with our Current Diagnostic Capacity\nThe Role of Diagnostics in Herds: Availability\, Challenges\, and How They’re Used\nThe Federal Strategy for Animal Surveillance\, Information Sharing\, and Disseminating Guidance\nRecognizing the Pandemic: Identifying the “AMR Pandemic” within the Pandemic and Disseminating Information and Guidance\nLeveraging Current Human Antibiotic-Use-Monitoring for AMR Pandemic Surveillance\nRecognizing the Pandemic: Producer Surveillance Methods and Identifying Secondary AMR infections in Animal Production\nDevelopment of New Animal Vaccines and Understanding Federal Regulations\nUnderstanding the Animal Diagnostic Communication Network (Labs\, Producers\, and Veterinarians)\nSources of Environmental Contamination and the Potential for Surveillance\n\nThis meeting is open to the public. Members of the public can choose to attend in-person (attendance will be limited) or view the meeting via webcast. Please visit the HHS 21st Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) website to register.
URL:https://globalbiodefense.com/event/paccarb-public-meeting-presidential-advisory-council-on-combating-antibiotic-resistant-bacteria/
LOCATION:Tysons Corner Marriott\, 8028 Leesburg Pike\, Tysons Corner\, VA\, 22182-2719\, United States
CATEGORIES:Conference,Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220919
DTEND;VALUE=DATE:20220924
DTSTAMP:20220924T162456Z
CREATED:20220824T161938Z
LAST-MODIFIED:20220924T162456Z
UID:56511-1663545600-1663977599@globalbiodefense.com
SUMMARY:Fungal Disease Awareness Week
DESCRIPTION:Fungal Disease Awareness Week is September 19–23\, 2022. CDC and partners have organized this week to highlight the importance of antifungal stewardship\, reducing resistance to antifungal drugs\, and recognizing serious fungal diseases early enough in the course of a patient’s illness to provide lifesaving treatment. \nSome fungal diseases go undiagnosed\, leading to serious illness and death. Increased awareness about fungal diseases is one of the most important ways we can improve early recognition and reduce delays in diagnosis and treatment. A key clue to when a sick person may have a fungal disease is that he or she is being treated with medicine for another type of infection but does not get better. \nWe encourage healthcare providers and patients to “Think Fungus” when symptoms of infection do not get better with treatment. The quicker doctors can diagnose the right illness\, the quicker patients can be treated the right way. \n \nIt’s important to consider fungal diseases in the context of the COVID-19 pandemic because the symptoms of some fungal diseases can be like those of COVID-19\, including  fever\, cough\, and shortness of breath. To provide appropriate care\, laboratory testing is necessary to tell if a person has a fungal infection or COVID-19. \nConfirming diagnosis of fungal infections can also help avoid unnecessary prescription of antifungals\, which could increase resistance to antifungal drugs. \nAntifungal drugs treat fungal infections by killing or stopping the growth of dangerous fungi in the body. Fungi can develop antimicrobial resistance\, when germs like bacteria and fungi develop the ability to defeat the drugs designed to kill them—that means the germs are not killed and continue to grow. Currently\, only a small number of antifungal drug types exist\, so resistance can severely limit treatment options.
URL:https://globalbiodefense.com/event/fungal-disease-awareness-week/
CATEGORIES:Awareness Event
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/09/fungal-awareness-week.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220920
DTEND;VALUE=DATE:20220925
DTSTAMP:20220829T233259Z
CREATED:20220829T233259Z
LAST-MODIFIED:20220829T233259Z
UID:56263-1663632000-1664063999@globalbiodefense.com
SUMMARY:21st Congress of the International Society for Human and Animal Mycology
DESCRIPTION:The 21st Congress of the International Society for Human and Animal Mycology will be \nHighlighted topics of interest include: \n\nVeterinary relevant and zoonotic fungal groups\nDevelopment of WHO priority pathogens list of public health importance\nAMR fungal infections global burden: surveillance challenges\, gap & opportunities: WHO GLASS pilot\nUnraveling the genetic determinants of virulence in Cryptococcus\nWHO first antifungals clinical & preclinical pipeline review\nDiagnostic Rounds Interactive session for diagnosis of emerging and re-emerging fungal infections\nAntifungal activity of antimicrobial synthetic peptides against Candida species of public health importance\nHigh rate of chronic pulmonary aspergillosis in active TB patients in Indonesia with GeneXpert positive?\nDevelopment of a breath-based diagnostic for valley fever\, an endemic fungal pneumonia\nInvestigation of in vitro antifungal susceptibility testing and genetic diversity of clinical isolates of Trichophyton benhamiae and Trichophyton eriotrephon in Iran\nShould we continue to use conventional doses of candins for all ICU patients?\nParadigm shift in the epidemiology of invasive fungal infections during COVID-19 pandemics\nCryptococcus qPCR assays: the future for routine mycology labs and clinical trials dealing cryptococcosis\nEvaluation of new tools for the diagnosis of histoplasmosis\nAgrochemicals potentiate multidrug resistance and alter virulence in Cryptococcus neoformans via hitch-hiking effect of aneuploidy\nFuture of molecular typing in fungi\nStanding Up FungiNet: Genomic epidemiology and surveillance of fungal diseases\nStandardization of diagnostic mycology laboratories\nWhy sporotrichosis and Paracoccidioidomycosis should be considered neglected tropical disease\n\nPlease visit the ISHAM website to register for the 21st Congress of the International Society for Human and Animal Mycology meeting.
URL:https://globalbiodefense.com/event/21st-congress-of-the-international-society-for-human-and-animal-mycology/
LOCATION:Hotel de Ashok\, 50\, Niti Marg\, Diplomatic Enclave\, New Delhi\, Chanakyapuri\, 110021\, India
CATEGORIES:Conference
ORGANIZER;CN="International Society for Human and Animal Mycology (ISHAM)":MAILTO:isham2022@congresscare.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220923
DTSTAMP:20220420T212311Z
CREATED:20220420T212042Z
LAST-MODIFIED:20220420T212311Z
UID:54799-1663718400-1663891199@globalbiodefense.com
SUMMARY:Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) Meeting
DESCRIPTION:The Scientific Advisory Committee on Alternative Toxicological Methods will meet 21-22 September 2022. \nThis is a Save-the-Date posting. Further details will be made available at the National Toxicology Program website closer to the meeting date.
URL:https://globalbiodefense.com/event/scientific-advisory-committee-on-alternative-toxicological-methods-sacatm-meeting/
CATEGORIES:Conference,Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220921T120000
DTEND;TZID=America/New_York:20220921T130000
DTSTAMP:20220921T172921Z
CREATED:20220921T172727Z
LAST-MODIFIED:20220921T172921Z
UID:56416-1663761600-1663765200@globalbiodefense.com
SUMMARY:Virtual Town Hall Series - Monkeypox Test Development and Validation
DESCRIPTION:The U.S. Food and Drug Administration (FDA) will host a virtual town hall for monkeypox test developers on 21 September 2022. The purpose of these town halls is to help answer technical questions about the development and validation of tests for monkeypox. \nThe FDA plays a critical role in protecting the United States from threats such as emerging infectious diseases\, including monkeypox . The FDA is committed to providing timely guidance to support response efforts to this public health emergency. \nThe guidance\, Policy for Monkeypox Tests to Address the Public Health Emergency\, includes policies specific to this public health emergency. \nThe FDA hosted a webinar on September 14\, 2022\, to discuss highlights of and answer questions about the final guidance. The presentation\, printable slides\, and transcript from that webinar are available at CDRH Learn under “Specialty Technical Topics”\, sub-section “Public Health Emergencies.”
URL:https://globalbiodefense.com/event/virtual-town-hall-series-monkeypox-test-development-and-validation/
CATEGORIES:Conference,Government Hosted
LOCATION:https://fda.zoomgov.com/j/1612083563?pwd=NklWOE1jUlU2dUVlNWtvQTNkdTM5UT09#success
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220922T083000
DTEND;TZID=America/New_York:20220922T170000
DTSTAMP:20220921T183353Z
CREATED:20220921T183322Z
LAST-MODIFIED:20220921T183353Z
UID:56423-1663835400-1663866000@globalbiodefense.com
SUMMARY:VRBPAC Meeting - Rebiotix Indication for Recurrent Clostridioides difficile Infection
DESCRIPTION:The Vaccines and Related Biological Products Advisory Committee (VRBPAC) will convene on 22 September 2022 to discuss the Biologics License Application # 125739 (BLA – 125739) from Rebiotix Inc. for a product\, Rebyota (Fecal Microbiota\, Live)\, with a requested indication to “reduce the recurrence of Clostridioides difficile infection (CDI) in adults following antibiotic treatment for recurrent Clostridioides difficile infection.” \nFDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. \nThe Docket Number is FDA-2022-N-1608.
URL:https://globalbiodefense.com/event/vrbpac-meeting-rebiotix-indication-for-recurrent-clostridioides-difficile-infection/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=vrahKrbyJaU
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220922T143000
DTEND;TZID=America/New_York:20220922T153000
DTSTAMP:20220921T203623Z
CREATED:20220921T203623Z
LAST-MODIFIED:20220921T203623Z
UID:56437-1663857000-1663860600@globalbiodefense.com
SUMMARY:Navigating Avian Influenza: From Prevention to Recovery
DESCRIPTION:Hear insights and information from APHIS and other experts on steps to take and what to expect during a bird flu outbreak during a free webinar on 22 September 2022. \nLearn from USDA and other experts about how to keep your flocks safe from highly pathogenic avian influenza (HPAI). This session is for enthusiasts\, farmers\, educators\, and anyone interested in signs and symptoms of HPAI\, what to watch out for during fall migration\, and how to develop an effective biosecurity and response plan. Hear about one educational farm’s experience managing a potential HPAI outbreak and get tips on how to keep your poultry flocks safe. \nPlease register for the Navigating Avian Influenza webinar in advance.
URL:https://globalbiodefense.com/event/navigating-avian-influenza-from-prevention-to-recovery/
CATEGORIES:Government Hosted
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/09/navigating-avian-influenza-usda.jpg
LOCATION:https://us02web.zoom.us/webinar/register/WN_z8GAVnu2SkiAfdqfMXgK0g
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220926
DTEND;VALUE=DATE:20220928
DTSTAMP:20220921T174333Z
CREATED:20220921T174333Z
LAST-MODIFIED:20220921T174333Z
UID:56420-1664150400-1664323199@globalbiodefense.com
SUMMARY:MAQC 2022 - Massive Analysis and Quality Control Society Conference
DESCRIPTION:The 5th Annual Meeting of the FDA/National Center for Toxicological Research (NCTR) – Massive Analysis and Quality Control Society (MAQC) 2022 Conference will be held September 26-27\, 2022\, at the U.S. FDA Headquarters\, White Oak Campus in Silver Spring MD. \nConference presentations\, abstracts\, and discussions will include themes around: Explainable/Reproducible AI/ML\, AI/ML in health-related datasets\, SARS-CoV-2 and public health\, Single-cell\, genomics\, image analysis\, reference samples\, reproducible science and more. \nHighlighted topics and presentations include: \n\nDARPA’s explainable AI (XAI) program: A retrospective\nDrug repurposing for COVID-19 using explainable machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection with real world data validation\nAn automated bioinformatic software testing and benchmarking platform to standardize the development of accurate\, reproducible\, and scalable omics analysis tools\nLeaSH: a High-Throughput COVID-19 Test to Profile Viral and Host Transcriptomes by Next Generation\nSequencing\nSome non-obvious factors that enhance or diminish observed and theoretical Illumina library complexity\nAI or Animal – A reproducibility perspective\nReproducible AI for supporting regulatory applications – a case study\nImproving preclinical pathology analysis with PathologAI\nExplainable approach for species identification using LIME\nEvaluation of mutagenic susceptibility of different stages in germ cell development of Caenorhabditis elegans using next generation sequencing\nIntegrated Calling and Evaluation of Gene Fusion Detection by Targeted RNA Sequencing of Reference Samples with Long and Short Reads\nMutual genome and transcriptome enrichment and sequencing in single cells with ResolveOME amplification chemistry to illuminate complex biological mechanisms\n\nPlease visit the Massive Analysis and Quality Control Society (MAQC) 2022 Conference website for more information and to register.
URL:https://globalbiodefense.com/event/maqc-2022-massive-analysis-and-quality-control-society-conference/
LOCATION:FDA White Oak Campus\, 10903 New Hampshire Ave\, Silver Spring\, MD\, 20993\, United States
CATEGORIES:Government Hosted,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220926T103000
DTEND;TZID=America/New_York:20220926T173000
DTSTAMP:20220907T151745Z
CREATED:20220907T151724Z
LAST-MODIFIED:20220907T151745Z
UID:56350-1664188200-1664213400@globalbiodefense.com
SUMMARY:IARPA PICARD Program Proposers' Day
DESCRIPTION:The IARPA Pursuing Intelligent Complex Aerosols for Rapid Detection (PICARD) program will host a Proposer’s Day on 26 September 2022 to introduce the PICARD program to potential proposers and to provide information on technical requirements and program objectives. The PICARD program intends to develop a fieldable sensing platform for the rapid identification of aerosol particles in plumes. This platform will address both point detection (in situ) and standoff detection capabilities that focus on the complexity of aerosols with non-uniform sizes\, structures\, and chemical composition as well as dispersion in challenging environments. \nThe goal of PICARD is to develop novel integrated hardware and software tools that will improve the current state of the art with respect to chemical specificity\, accuracy\, and sensitivity. \nThe PICARD Proposers’ Day is a hybrid event that will be broadcast via the Webex video conference platform for remote attendees. In person participation is encouraged to facilitate information exchange and team forming. For planning purposes\, the venue is located near the Ballston Metro Station in Arlington\, VA. A recorded video of the meeting will be made available to the public on the IARPA website after the event. \nProposers’ Day Registration Closes: Friday\, September 16\, 2022 at noon EDT. Please visit IARPA’s PICARD Proposers’ Day website for more information. \n 
URL:https://globalbiodefense.com/event/iarpa-picard-program-proposers-day/
LOCATION:Ballston Metro Station\, Arlington\, VA\, United States
CATEGORIES:Government Hosted
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/09/iarpa-picard-intelligent-complex-aerosol-rapid-detection.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220928
DTEND;VALUE=DATE:20220930
DTSTAMP:20240623T193106Z
CREATED:20220921T190315Z
LAST-MODIFIED:20240623T193106Z
UID:56428-1664323200-1664495999@globalbiodefense.com
SUMMARY:GBHI 2022 - 5th Annual Global Bioequivalence Harmonization Initiative Meeting
DESCRIPTION:The goal of the Global Bioequivalence Harmonization Initiative (GBHI) conference is to offer the most informative and up to date science and regulation of bioequivalence in global drug development.  \nThe FDA AAPS EUFEPS 5th Annual GBHI Meeting will be held 28-29 September 2022. GBHI workshop provides an open forum for pharmaceutical scientists from academia\, industry and regulatory agencies to discuss various bioequivalence topics at issue including: \n\nFed vs fasted studies for immediate release dosage forms\nRelevance of excipients\, disintegration/dissolution specificities\, drug substance properties and physiological GI conditions\nReplicate design for BE of Highly Variable Drugs\ntwo-stage design and Pharmacokinetic modelling as supportive tools for BE assessment\nScientifically-based approaches for a waiver of clinical endpoint trials\nStudy design and acceptance criteria\n\nThis conference is intended for leaders in Academia\, the Pharmaceutical and Biotechnology Industry (PhRMA\, BIO\, GPhA)\, contract research organizations\, API manufacturers\, and domestic and international regulatory agencies in positions to affect the science and regulation of drug discovery and development\, who wish to stay abreast of the national and international initiatives affecting the development of safe and effective pharmaceutical drug products. \nPlease visit the FDA’s Global Bioequivalence Harmonization Initiative (GBHI) conference website for more information.
URL:https://globalbiodefense.com/event/gbhi-2022-5th-annual-global-bioequivalence-harmonization-initiative-meeting/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220929
DTEND;VALUE=DATE:20221001
DTSTAMP:20220922T194342Z
CREATED:20220922T194342Z
LAST-MODIFIED:20220922T194342Z
UID:56478-1664409600-1664582399@globalbiodefense.com
SUMMARY:Managing for Supply Chain Resilience Course
DESCRIPTION:NDIA’s Business Institute and Carnegie Mellon University’s Software Engineering Institute will host a Managing for Supply Chain Resilience Course from 29-30 September 2022 to will explore the sources and types of supply chain risks and provide practical guidance on how to manage these in alignment with business strategy. \nThe course includes an examination of prominent frameworks and standards (e.g.\, NIST Special Publication 171 and the Cybersecurity Maturity Model Certification) and the fundamental tools (e.g.\, Service Level Agreements\, and Software Bill of Materials) required to effectively quantify and manage supply chain risk.  No prior technical cybersecurity knowledge or experience is required. \nPlease visit NDIA’s Managing for Supply Chain Resilience Course event page for more information and registration.
URL:https://globalbiodefense.com/event/managing-for-supply-chain-resilience-course/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220929T110000
DTEND;TZID=America/New_York:20220929T150000
DTSTAMP:20220924T161732Z
CREATED:20220924T161603Z
LAST-MODIFIED:20220924T161732Z
UID:56507-1664449200-1664463600@globalbiodefense.com
SUMMARY:National Biodefense Science Board Public Meeting
DESCRIPTION:The next public meeting of the National Biodefense Science Board (NBSB) will take place on Thursday\, September 29. \nJoin NBSB members\, distinguished guests\, federal leaders\, and subject matter experts exploring topics such as how best to support rural and underserved communities during the COVID-19 pandemic\, use of virtual healthcare during disasters\, and health system operational data considerations during a health emergency. For additional details and meeting agenda topics\, please see the NBSB Public Meeting page. An agenda for the meeting is posted on the website. \nHighlighted agenda items include: \n\nReadiness and Resilience Working Group Readout\nCountermeasures and Operational Research Working Group Readout\nDisaster and Public Health Emergency Training Needs\, Challenges\, and Opportunities for the Health Workforce in the United States\nOpen Discussion – Additional Key Biodefense Lessons from COVID-19\n\nAdvanced registration is required. To register for the meeting and for additional information\, visit the NBSB Public Meeting page. \nRegister to Address the NBSB\nThe NBSB are inviting people with expertise or experience related to the collection\, analysis\, and operational use of health data to improve access to and resilience of virtual health care to address the Board and/or experience and expertise addressing rural and underserved communities during the COVID-19 pandemic. \nWe are particularly interested in hearing stakeholder input related to the following topics: \nOperational Health Data for Disaster Response\n\nWhat are your concerns about the confidentiality of your health data or how it might be used?\nWhat are your concerns with the current HHS data reporting requirements for health systems\, including the format\, timing\, and extent of data that must be submitted?\nShould data reporting requirements\, or modified requirements\, be continued after the COVID-19 reporting stops?\nWhat are the current training needs for healthcare staff to meet the requirements for collection and reporting of health data?\nWhat is the level of effort (i.e. staffing and person-time) required to satisfy all of the current health system reporting requirements?\nIf your health care or public health organization has agreements in place to share information among regional partners\, do you have processes in place to improve data sharing during a disaster? Has data sharing during disasters led to an improved disaster response?\nIf your health care or public health organization has agreements in place to share information among regional partners\, do you have any special measures in place to ensure that rural and underserved communities are represented?\n\nVirtual Healthcare for Disaster Response\n\nWhat could be done to improve the reliability and availability of internet access and the appropriate computers or software? If available\, is the use of telephone or radio an acceptable option for medical care during a disaster?\nWhat are your concerns about the continuity of care\, including the availability of your own medical history and proper recording of virtual care?\nAre there adequate resources in place to ensure that you receive the medications you need during a disaster?\nWould you be willing to have a “family visit” for healthcare\, where multiple people are treated on the same virtual visit?\n\nUpdate: NBSB currently has as many public speakers as can accommodated in the time available\, so please send written comments on related topics to NBSB@hhs.gov\, which will be shared with the board members ahead of the meeting. Additional meeting materials will be made available to the public on the NBSB Public Meeting page.
URL:https://globalbiodefense.com/event/national-biodefense-science-board-public-meeting-4/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221003
DTEND;VALUE=DATE:20221008
DTSTAMP:20220922T183847Z
CREATED:20220922T183847Z
LAST-MODIFIED:20220922T183847Z
UID:56471-1664755200-1665187199@globalbiodefense.com
SUMMARY:AAAR 2022 - American Association for Aerosol Research
DESCRIPTION:Experts and stakeholders in aerosol science of infectious diseases and indoor air quality will gather in North Carolina this October. \nThe 40th AAAR Annual Conference of the American Association for Aerosol Research will take place 3-7 October 2022 in Raleigh\, North Carolina. \nSpecial Symposia designed to bridge multiple areas and promote cross-disciplinary interaction will be held on the following topics: \n\nBiomass Combustion: outdoor/indoor transport and indoor air quality\nAerosol Physical Chemistry and Microphysics\nAerosol Science of Infectious Diseases: What we’ve learned and still need to know about transmission\, prevention\, and the one health concept\nAerosol sources and constituents of emerging importance and their impacts across spatial scales\n\nHighlighted topics and sessions include: \n\nOptimization of a Wetted Wall Cyclone for Pathogen Collection\nImpact of Chemically Reductive Trace Air Contaminants on Non-thermal Plasma Inactivation of Airborne Viruses\nModeling of the Atmospheric Process of Cyanobacterial Toxins in Algal Aerosol\nAssessment of the Effectiveness of a Hygroscopic Coating on the Conservation of MS2 Viability during Aerosol Sampling with MCE Filters\nContinuous Fluorescent Bioaerosol Measurements for 18 Months Combined with Filter Sampling Validation\nCharacterization of Aerosol in Poultry Farms with Low-Cost Sensors and Research-Grade Instruments\nComparison of Airborne Bacterial Diversity Collected by Passive and Active Air Sampling\nPerformance of Low-cost PurpleAir Sensor in Monitoring Indoor Aerosols\nInfluence of UV Irradiation and Environmental Factors on the Size-Dependent Survivability of Bioaerosols\nWhat is the Best Cleaning Method the Public Can Use to Remove Bacillus Spores from Indoor Surfaces?\nAntibiotic Resistance Genes in Air Near Farms\nFate of Inhaled Particles in the Lungs of Ferrets\nPerformance of N95 Filtering Facepiece Respirators Used with Skin Protectants: Manikin-based Study\nSeasonal Impacts on Microbiome Diversity and Antibiotic Resistance Patterns in Aerosolized Bacteria in a Dairy Facility\nAgricultural Contributions to Fluorescent Bioaerosol Measured by the WIBS at the AGINSGP Campaign at the Southern Great Plains Site\nQualitative Analysis of Bioaerosol Chemical Composition and Shift by Means of 1HNMR\nU.S. EPA Progress on Developing Performance Testing Protocols and Targets for Particulate Matter Air Sensors\nToxicological Impact of Secondary Organic Aerosol Compounds in Air-Liquid-Interface Exposed Lung Cell Models\nTrapped in the Inversion Layer: Composition and Morphology of Single Aerosol Particles in the Urban Arctic Winter\nExploring the Chemical Evolution of Aerosol Particle Composition and Physical Properties using Single Particle Levitation\nGlobal vs. Local Dose Deliveries of Airborne Particles through Dosimetric Aerosol in Vitro Inhalation Device (DAVID)\nUltrafine Aerosol Particle Formation and Impacts in Houston during TRACER\nEffects of Wet Removal on Aerosol Mass and Chemical Composition\nInvestigating the Fate of wildfire Smoke in Homes\nImpact of Do-It-Yourself and Commercial Air Cleaner Use on Residential PM2.5 in a Smoke-Impacted Community\nDeveloping National Exposure Models for Source-Specific Primary Particulate Matter Concentrations Using Aerosol Mass Spectrometry Data\nThe Peroxy Radical Fates during Heterogeneous Oxidation of Organic Aerosols\nComparison of Organic Aerosol Composition and Source Distributions across Different Urban Microenvironments\nCharacterization of VOC and Particle Emissions in Exhaled Air during Vaping\nPersonal Exposure of Domestic Dogs and Their Owners to Airborne Per- and Polyfluoroalkyl Substances (PFAS)\nRisk Assessment of Ambient Toxic Aerosols and Gases Among Firefighters During Fire Training\nSeasonal Variation in Ambient Air Pollutants and Influence of Meteorological Factors in an Urban Environment\nCharacterizing the Seasonal Sources of Urban Organic Aerosol Using the Non-Targeted High-Resolution Mass Spectrometry and Factor Analysis\nVolatile Chemical Product Contributions to the Urban Secondary Organic Aerosol Burden\nMeasuring and Modeling Ultrafine Particle Growth by Isoprene Ozonolysis Secondary Organic Aerosol\n\nPlease visit the American Association for Aerosol Research 2022 Conference website for more information and to register.
URL:https://globalbiodefense.com/event/aaar-2022-american-association-for-aerosol-research/
LOCATION:Raleigh Convention Center\, 500 S Salisbury St.\, Raleigh\, NC\, 27601\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221004
DTEND;VALUE=DATE:20221008
DTSTAMP:20220420T231323Z
CREATED:20220420T231135Z
LAST-MODIFIED:20220420T231323Z
UID:54819-1664841600-1665187199@globalbiodefense.com
SUMMARY:ESCMID-ASM Drug Development to Meet the Challenge of AMR
DESCRIPTION:The 2022 ESCMID/ASM Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance is scheduled to take place Oct. 4-7\, 2022 in Dublin\, Ireland. \nAntimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority by national and international bodies. Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID)\, this multidisciplinary meeting will address the challenges\, opportunities and current requirements for antimicrobial drug development to address antimicrobial resistance. \nAbstracts can be submitted until 27 June 2022 in the following categories: \n\nDrug discovery\nDrug development\nNovel therapeutics\nPreclinical development\nNew antibacterial classes\nNon-traditionals\nClinical development\nStewardship\n\nPlease visit the ESCMID website to register for the Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2022.
URL:https://globalbiodefense.com/event/escmid-asm-drug-development-to-meet-the-challenge-of-amr/
LOCATION:Dublin\, Ireland\, Dublin\, Ireland
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221005
DTEND;VALUE=DATE:20221006
DTSTAMP:20220922T145702Z
CREATED:20220922T145702Z
LAST-MODIFIED:20220922T145702Z
UID:56457-1664928000-1665014399@globalbiodefense.com
SUMMARY:Study Data Standards Update for FDA CBER
DESCRIPTION:FDA’s Center for Biologics Evaluation and Research (CBER)  will host a free virtual format workshop on 5 October 2022 entitled Study Data Standards Update for CBER: Your Guide to a Successful Submission. \nCBER will discuss CBER’s support and requirement starting March 15\, 2023 for the Standard for the Exchange of Nonclinical Data (SEND) \, which was published in the Federal Register on July 14\, 2020\, and the addition of SEND for CBER to the FDA Data Standards Catalog. \nFDA will discuss the brief background of the new requirement and how SEND will aid CBER reviewers. The webinar will also address common issues in submission data. \nINTENDED AUDIENCE\n\nRegulatory science and regulatory affairs professionals working on clinical and non-clinical data submissions for BLAs/NDAs/ANDAs/INDs to CBER\nConsultants focused on clinical and non-clinical data submission\nHealthcare professionals specializing in clinical and non-clinical data\nForeign regulators\n\nFDA RESOURCES\n\nFederal Register Notice regarding SEND for CBER\nFDA Data Standards Catalog\nStudy Data Technical Conformance Guide\nFDA Study Data Standards Resources\nEmail: cber-edata@fda.hhs.gov\n\nPlease visit FDA’s Study Data Standards Update for CBER: Your Guide to a Successful Submission meeting webpage for more information.
URL:https://globalbiodefense.com/event/study-data-standards-update-for-fda-cber/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221006T083000
DTEND;TZID=America/New_York:20221006T130000
DTSTAMP:20220921T202014Z
CREATED:20220921T201913Z
LAST-MODIFIED:20220921T202014Z
UID:56435-1665045000-1665061200@globalbiodefense.com
SUMMARY:VRBPAC Meeting - Vaccine Strain Selection 2023 Southern Hemisphere Flu Season
DESCRIPTION:The FDA Vaccines and Related Biological Products Advisory Committee will convene on 6 October 2022 in open session to discuss the Strain Selection for the Influenza Virus Vaccines for the 2023 Southern Hemisphere Influenza Season. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. Interested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. The Docket Number is FDA-2022-N-1745 \nPlease visit the FDA VRBPAC Meeting website for more information.
URL:https://globalbiodefense.com/event/vrbpac-meeting-vaccine-strain-selection-2023-southern-hemisphere-flu-season/
CATEGORIES:Government Hosted
LOCATION:https://youtu.be/qazitJMHZK4
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221012
DTSTAMP:20220921T200930Z
CREATED:20220921T200613Z
LAST-MODIFIED:20220921T200930Z
UID:56431-1665446400-1665532799@globalbiodefense.com
SUMMARY:FDA NanoDay Symposium 2022
DESCRIPTION:The FDA NanoDay Symposium 2022 will be held on 11 October 2022. The event will address drug development of products that contain nanomaterials in their formulation and how the newly finalized guidance to industry for products that contain nanomaterials can be implemented in filings to the FDA. \nHighlighted topic areas include: \n\nPrimary Chemistry Manufacturing and Controls (CMC) and nonclinical hurdles for developing products that contain nanomaterials\nDevelopment and Characterization of Generic Drug Products Containing Nanomaterials\nConsiderations for the Quality\, Safety and Efficacy of Prophylactic Lipid Nanoparticle mRNA Vaccines\nCase studies on the development of the COVID mRNA lipid nanoparticle vaccine products\nFuture of Continuous Manufacturing of Drug Products Containing Nanomaterials\nEfforts to establish standards and standard methods for monitoring products that contain nanomaterials\nA contextualized discussion of the development of the COVID mRNA lipid nanoparticle vaccine products\nA nonclinical perspective of developmental challenges of products that contain nanomaterials\nSafety Evaluation of Food Contact Substances Containing Nanomaterials\n\nThe intended audience includes: Regulatory science and regulatory affairs professionals working on drug products\, including biologicals\, that contain nanomaterials and submit IND/NDA/BLA/ANDA applications for FDA review; researchers working on applications of nanotechnology for pharmaceutical products\, analytical methodology for control of pharmaceuticals that contain nanomaterials\, and nonclinical studies to support human clinical trials; and foreign regulators who review comparable pharmaceutical products that contain nanomaterials. \nPlease visit the FDA’s NanoDay Symposium 2022 website for more information. \nFDA RESOURCES\n\nGUIDANCE DOCUMENT: Drug Products\, Including Biological Products\, that Contain Nanomaterials – Guidance for Industry; APRIL 2022\nGUIDANCE DOCUMENT: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology – Guidance for Industry; JUNE 2014\nGUIDANCE DOCUMENT: Liposome Drug Products: Chemistry\, Manufacturing\, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation; APRIL 2018\nGUIDANCE DOCUMENT: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs\, Including Well-Characterized\, Therapeutic\, Biotechnology-derived Products – Guidance for Industry; NOVEMBER 1995
URL:https://globalbiodefense.com/event/fda-nanoday-symposium-2022/
CATEGORIES:Continuing Education,Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221011T090000
DTEND;TZID=America/New_York:20221011T120000
DTSTAMP:20220923T194931Z
CREATED:20220923T194822Z
LAST-MODIFIED:20220923T194931Z
UID:56491-1665478800-1665489600@globalbiodefense.com
SUMMARY:Epidemics That Didn't Happen
DESCRIPTION:Join Resolve to Save Lives for a dynamic conversation to mark the release of the second edition of “Epidemics that Didn’t Happen.” This virtual event and new report will illustrate how global and local investments in preparedness\, combined with swift\, strategic responses by public health authorities\, can transform the trajectory of outbreaks\, saving lives and preventing suffering. \nThe latest “Epidemics that Didn’t Happen” report celebrates successful outbreak responses from around the world that demonstrate the returns—in lives saved—of investing in preparedness and response systems. These examples—from Brazil\, Burkina Faso\, Democratic Republic of Congo\, Guinea\, Indonesia\, India and Tanzania—are a testament to the power of preparedness and a roadmap for future success in preventing epidemics. \nCOVID-19 and recent outbreaks of monkeypox and polio have highlighted how vulnerable the world is to infectious diseases. But every day\, public health workers stop epidemics before they start.\nJoin Resolve to Save Lives for a dynamic conversation to mark the release of the second edition of “Epidemics that Didn’t Happen.” This virtual event and new report will illustrate how global and local investments in preparedness\, combined with swift\, strategic responses by public health authorities\, can transform the trajectory of outbreaks\, saving lives and preventing suffering. \n\nWelcome & Opening Remarks – Dr. Tom Frieden\, President and CEO\, Resolve to Save Lives\nKeynote: Reforming Global Health for the Next Pandemic – Precious Matsoso\, former director-general of South Africa’s Department of Health and former chair of the World Health Organization’s Executive Board\nSnapshot of Epidemics that Didn’t Happen\, 2022 – Amanda McClelland\, SVP\, Resolve to Save Lives\nPanel Discussion: Lessons Learned from Successful Outbreak Responses – Featuring: Márcio Garcia\, Health Surveillance Superintendent\, Rio de Janeiro Municipal Health Secretariat ; Representative from Indonesian Red Cross Society (invited)\n\nPlease visit the Resolve to Save Lives’ Epidemics That Didn’t Happen event site for more information.
URL:https://globalbiodefense.com/event/epidemics-that-didnt-happen/
CATEGORIES:Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221013T120000
DTEND;TZID=America/New_York:20221013T130000
DTSTAMP:20220921T205205Z
CREATED:20220921T205205Z
LAST-MODIFIED:20220921T205205Z
UID:56440-1665662400-1665666000@globalbiodefense.com
SUMMARY:Quality Considerations for MAM for Therapeutic Proteins
DESCRIPTION:The multi-attribute method (MAM) is a liquid chromatography-mass spectrometry (LC-MS) based peptide mapping approach used for the identification and quantitation of product quality attributes (PQAs) in therapeutic proteins. \nThe U.S. FDA Center for Drug Evaluation and Research (CDER)\, Emerging Technology Program (ETP) has assessed the use of MAM in quality control environments and laboratory resources have been developed to improve the FDA’s understanding of the approach. \nThis meeting will discuss: \n\nHow the LC-MS based multi-attribute method can be used for quality control of therapeutic proteins\nHow the multi-attribute method can detect multiple product quality attributes or critical quality attributes within a single LC-MS run\nKey considerations for implementation of the multi-attribute method\, including risk assessment\, method validation\, new peak detection\, and conventional method comparisons\n\nFor advance registration\, please visit the MAM for Therapeutic Proteins meeting page
URL:https://globalbiodefense.com/event/quality-considerations-for-mam-for-therapeutic-proteins/
CATEGORIES:Government Hosted
LOCATION:https://fda.zoomgov.com/webinar/register/WN_LKO4FXAlSfSuP89383sikg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221014
DTEND;VALUE=DATE:20221020
DTSTAMP:20220923T201223Z
CREATED:20220420T204952Z
LAST-MODIFIED:20220923T201223Z
UID:54794-1665705600-1666223999@globalbiodefense.com
SUMMARY:65th Annual Biosafety and Biosecurity Conference
DESCRIPTION:The ABSA’s 65th Annual Biosafety and Biosecurity Conference will be held 14-19 October 2022 in a hybrid virtual and in-person format in Milwaukee\, Wisconsin. \nThe event offers intensive professional development courses over three full days of state-of-the-art keynotes\, papers\, and panels highlighting best practices and hands-on skills crucial for today’s biosafety and biosecurity professionals. \nApproximately 700 attendees are expected and 70 exhibits will showcase the latest in laboratory biosafety and biosecurity products and services. \nTopics of interest for this meeting include: \n\nAgent Inactivation\nAnimal Biosafety\nArthropods and Biosafety\nBehavior/Enhancing Compliance\nBSL3-Ag or Large Animals\nBiosecurity\nCOVID-19\nDisinfection/Biowaste Management\nEmergency Response\nFacilities/Equipment (BSL-3)\nFacilities/Equipment (General)\nHuman Source Materials Mammalian Cell Lines\nIndustrial Biosafety\nInfectious Substance Transportation\nMicrobiology and Molecular Biology\nOccupational Health/Medical Surveillance/PE\nPractices/PPE (BSL-3)\nPractices/PPE (General)\nProgram Management\nPublic Health\nRegulatory Issues\nRisk Assessments\nShipping/Permits\nSynthetic Biology\nTraining\n\nSince ABSA International’s core purpose is dedicated to promoting and expanding biosafety and biosecurity expertise\, this is an excellent opportunity to display and discuss your products and services to an international audience. \nPlease visit the ABSA’s Annual Biosafety and Biosecurity Hybrid Conference 2022 website for more information.
URL:https://globalbiodefense.com/event/65th-annual-biosafety-and-biosecurity-conference/
LOCATION:Wisconsin Center\, 400 W. Wisconsin Ave.\, Milwaukee\, WI\, 53203\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221019
DTEND;VALUE=DATE:20221022
DTSTAMP:20220922T140954Z
CREATED:20220922T140800Z
LAST-MODIFIED:20220922T140954Z
UID:56448-1666137600-1666396799@globalbiodefense.com
SUMMARY:GSRS22 - 12th Global Summit on Regulatory Science
DESCRIPTION:GSRS22: The 12th Global Summit on Regulatory Science will be held from 19-21 October 2022 in Singapore. \nConvening under a theme of “Advances in Nanotechnology for Food and Medical Products: Innovations\, Safety and Standards”. the Summit will highlight topics including: \n\nNanomaterials for Gene Delivery\nNanotechnology in Agri-Products\nEmerging Nanomaterial Contaminants in Food\nGeneric Medical Products Containing Nanomaterial\nRole of Nanotechnology in Precision Medicine\nInnovation in Nanotechnology for Food\n\nThe Global Summit is free to attend\, but registration is required to attend the conference. \nThis event is being co-hosted by Singapore Food Agency (SFA) and the Global Coalition for Regulatory Science Research (GCRSR). \nPlease visit the GSRS22 website to register.
URL:https://globalbiodefense.com/event/gsrs22-12th-global-summit-on-regulatory-science/
LOCATION:Orchard Hotel Singapore\, 442 Orchard Road\, Singapore\, 238879\, Singapore
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221019T093000
DTEND;TZID=America/New_York:20221019T123000
DTSTAMP:20220922T190024Z
CREATED:20220922T185728Z
LAST-MODIFIED:20220922T190024Z
UID:56475-1666171800-1666182600@globalbiodefense.com
SUMMARY:CBRN Threats and Challenges - Fall Quarterly Update
DESCRIPTION:The NDIA will host a CBRN Threats and Challenges Fall Quarterly Update Forum on 19 October 2022. \nThis quarterly meeting is set to provide a SECRET-level classified update from government representatives in the Chemical and Biological Defense Program (CBDP). This update will inform industry and government attendees about the CB Threat concerns that the DASD is focused on and highlight the priority efforts to address those threats. The objective is to improve understanding across the community and help them to focus their efforts and resources in ways that align to the CBDP’s priorities. \nSpeakers include \n\nIan Watson\, Deputy ASD for Chemical and Biological Defense\nDarryl Colvin\, JPEO CBRND\n\nThis is a classified event. \nPlease visit NDIA’s CBRN Threats and Challenges – A Classified Update event page for more information.
URL:https://globalbiodefense.com/event/cbrn-threats-and-challenges-fall-quarterly-update/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221024T110000
DTEND;TZID=America/New_York:20221024T172000
DTSTAMP:20220905T180114Z
CREATED:20220905T180114Z
LAST-MODIFIED:20220905T180114Z
UID:56285-1666609200-1666632000@globalbiodefense.com
SUMMARY:Board of Scientific Counselors\, National Center for Health Statistics
DESCRIPTION:The CDC has announced the Board of Scientific Counselors\, National Center for Health Statistics (BSC\, NCHS) will convene 24 October 2022 in a live broadcast public meeting. \nThe Board is charged with providing advice and making recommendations to the Secretary\, Department of Health and Human Services; the Director\, CDC; and the Director\, NCHS\, regarding the scientific and technical program goals and objectives\, strategies\, and priorities of NCHS. \nThe meeting agenda will include a Center update by the NCHS Director in addition to updates on NCHS data collection\, analysis\, and reporting activities\, including upcoming changes to the National Hospital Ambulatory Medical Care Survey (NHAMCS); status of a National Ambulatory Medical Care Survey (NAMCS) pilot and plans for obtaining clinician visit data; a new project to improve metadata and catalogs for the public to access restricted use data files; and new releases of linked data sets. The Board’s Workgroup to Consider and Assess Measures of Discrimination for Use in NCHS Surveys will brief the Board with findings from 6 months of information-gathering and assessment work. The Committee will reserve time for public comment at the end of the day. Meeting times and topics are subject to change as priorities dictate. \nMeeting Information: Please visit the BSC\, NCHS website for details. Further information and the meeting agenda will be available on the BSC website\, including instructions for accessing the live meeting broadcast.
URL:https://globalbiodefense.com/event/board-of-scientific-counselors-national-center-for-health-statistics/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
END:VCALENDAR